{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-041404","form_type":"8-K","ticker":"STRO","cik":"0001382101","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.748878+00:00","generated_at":"2026-06-11T16:56:50.207706+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sutro Q2 2023: cash $358M, revenue $10.4M, initiates pivotal luvelta trial, Blackstone deal","bullets":["Cash, equivalents and marketable securities $358.3M; Vaxcyte shares valued at $33.3M; runway into H1 2025.","Revenue $10.4M (down from $28.1M YoY); total operating expenses $56.6M (up from $47.5M).","Initiated REFRaME Phase 2/3 pivotal study for luvelta in platinum-resistant ovarian cancer; enrollment underway.","Received $140M upfront from Blackstone royalty monetization; eligible for up to $250M milestone payments.","Luvelta endometrial cancer data to be presented at ESMO 2023; updated ovarian data expected H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-041404","json":"https://secwatch.observer/filing/0000950170-23-041404.json","markdown":"https://secwatch.observer/filing/0000950170-23-041404.md","text":"https://secwatch.observer/filing/0000950170-23-041404.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1382101/000095017023041404/0000950170-23-041404-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1382101/000095017023041404/stro-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T16:56:50.207706+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a04af4e1bf05c8713a7045e16f33971339bed964","claim":"SUTRO BIOPHARMA, INC. reported financial results for the second quarter of 2023.","evidence_excerpt":"On August 10, 2023, Sutro Biopharma, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017023041404/0000950170-23-041404-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter of 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}